TCS-OX2-29

TCS-OX2-29 is a pharmacological tool used in scientific research. It is a selective antagonist for the orexin receptor OX2, which is involved in the regulation of sleep-wake cycle, appetite, and mood. TCS-OX2-29 is used to study the role of the orexin system in various physiological and pathological processes.

History

TCS-OX2-29 was first synthesized and characterized by scientists at the Takeda Pharmaceutical Company in Japan. It was developed as part of a research program aimed at discovering new treatments for insomnia and other sleep disorders.

Pharmacology

TCS-OX2-29 is a potent and selective antagonist for the OX2 receptor. It binds to the receptor and prevents it from being activated by the neuropeptide orexin, thereby inhibiting the effects of orexin in the body. This can lead to increased sleepiness and decreased appetite, among other effects.

Uses

TCS-OX2-29 is primarily used in scientific research to study the role of the orexin system in various physiological and pathological processes. For example, it has been used to investigate the role of orexin in the regulation of sleep-wake cycle, appetite, and mood. It has also been used to study the potential therapeutic effects of OX2 receptor antagonists in conditions such as insomnia, narcolepsy, and obesity.

Safety

As a research tool, TCS-OX2-29 is not intended for human consumption. Its safety and potential side effects have not been thoroughly studied in humans.

See also

• Orexin receptor
• Orexin
• Takeda Pharmaceutical Company

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

   This article is a neuroscience stub. You can help WikiMD by expanding it!